what difference is a pleasure for me to adthe possibility to address this important meeting of you see， like， of course， i would have。

refer to be the背痛。

but i'm glad that we will soon see each other by up first in organo and little on incimen at the meeting of CSCO。

today， you ask me to呃review the progress in the treatment of informer as we see uh it now i will go through the youth spectrm of informer。

it， of course， because of that， i will have to be rather brief， let's start with augical informer。

today， we cure more than nineteen percent of the patients many， if they are in early stages a bit less in advance disease。

and as you can see here， there has been a continuous improvement during the last decades。

if we compare the mortality inpatients with um auginformer and the normal population， we see that there is still an excess of mortality inpatients with auganinforma。

and in order people， as you can see， here compare to the normal population and also inpatienence with advance a disease。

y统义致性early stages第。

survival expectancy is almost as the same。

but the main point is here that uh the improvement， as you see here in older patients has been much less。

pronounce ed in younger patience。

and the other point， if you look many in nurly stages is that after ten or more years， there are more patients dying before of second tumo today is the prixxicties ties then of toxxicties than of talinforma。

and therefore， the primary focus of research today is not only to improve today of responsate late to minimize toxicity。

now uh， in order to minimize toxicity， we have probably to always use the intensity of the treatment that we have been used。

to employ in the last decades。

but how can we select in early stages patients who do not need rato tavapand do can be to tavp alone。

well， do get。

we know that this is possible in the majority of the patience by using interimpact。

呃，perup ps together with a liquid biopsy results in order to。

avoid graeral be in bastience in complepleplemake ablic response。

the other question is， can we improve further the outcome in advanced stages by um improving what we can achieve with the standard ABVD or beacop。

by adding the took you up all the check point point individuals， and this is largely probably possible， but we do not afforsaid to find al um demonstration。

so。

一个，although auscaninformer is to get usually curable， we can still improve the outcome imppatients wraf， a very high。

this disease of the beginning。

those are very few less than ten percent。

the most important loop where we can improve our bastiwho who steel。

a positive pet at interrem evaluation and all their patients where we still do not do very well at the moment。

combining a risk adapted approach。

calculating the risk the beginning， but mainly using the response adopted treatment based on pet and liquid biopsy， we should be able to further improve。

uh， the outcome soon， the am convinced by doatso uh， by adding。

so you antibody and target ted treatso uthe be approachsoon， the one percent mark of curry。

now let's switch to not last， get informers and do sars with poliqual and informers。

as you know， stage one best stage one， a flliqular informer we cure today about twitter of the patients。

differences， the situations in baseally advance for equal of informer， since this disease remains in the very vast majority of the cases inquable， but the medium overall survival as tremenmendous improve the last last。

if you see， here is standard data， the studidy data， we are similar data in our a data is， and you see that today， the medium。

survival of our patients diagnose today with for liqual， al informer is eighteen perup ps twenty， twenty compaare to ten years comp ps twenty years ago， and this is even more so in younger ger patients。

this is many ly uneuropean thirty and americamerican thirty european thirty started in our database， together with london and above salona。

and you see that impatience in younger than thirty years um。

their median survivors can be expected today today to be more in thirty years， and ninety percent of them will be alive after at ten years。

but we are still。

on my norvity of the patients who do not do very well and um what has been been shown in in serseries in the last， it is the fact that。

the most important porchnosic factors is whether so patient is relauing before or after twenty twenty months。

the so coport twenty four， as you can see here patients within a relaation after or not relaation， after twenty four monounts of much tinos than patients relapence within two years。

and this is ensision in all series。

but now we're going to make quesquestions。

how can we predict at the beginning？ what the patients will be BOD twenty four positive or not？。

and if we can do that。

how can we。

第一个out should retredidisplations would be in BOD twenty four， a positive in order to improve as the outcome。

we are seen that the usual呃score risk a clinical um。

our i'm not a sufficient。

呃，the different flippies， the brarama a score risk index are insufficient to identify the POD twenty for a positive。

and different people and our coupes us of lide to and do the clinical risk score as the momotation of single general of a few genes in order to improve the porchnostic capacity。

a of the score， but this are prove not to be very呃useful。

so the porchnostic scoring system are still a very limited discrimination capacity for determining under the beginning， who will be pud d for。

and more important than that for the time being， we have not been able to devise are better。

he will tell appeal a better treatment that we should give from the very beginning to the patients will later。

one be POD twenty four in order to approve their outcome。

so there is still about ten to twenty percent of the patients would we do badly still today。

now another uh， another important um uh improvement in呃，the um statement of politiclar informer are been the uh discovery that uh h。

we do not always use tem motea p， but we can always HHMM results ts uh using the so called keamo free approach。

this was developed a lot in in in switland。

and by showing that the combination of we took ation and and little little little sube， it， we took him alone。

and this is the devote stuwhich was been publishing ing new new a few years agagwhich， which a diffediffeaporwas squsquare was compared。

the demal。

we took him up up MA took up up a took apaland。

we tqual ininform as you can see here， there is no difference。

what's forever？。

so uand， even in your lunn， uh archemo is not doing better than squsquare as as an initial uh treatment。

so what we can呃say呃today。

is that嗯。

in first line。

呃，reatment for philicullar a informers。

we are still many possibilities。

in some patients， we still do watching weight or we can start， which we took him up alone。

if the disease is very england or we can start， if the disease is a little it bengland with square， or if the ginase is a glassive at the beginning， we start with are m。

what about the a second line a treatment？as you know， for the time being， the PI to gain any beatles， which were very promising， have been suspended because of a lot of a toxity。

but there， i also some good news and not only bad news for a second line eh treatment。

and this is a fact that。

both cafety ells staatment as well as um be specific。

a monocononal antibodies are thought to be very， very efficicous in relaasing patients within twenty four months or in even resistance uh patients。

of course， we still do not know exactly when to use that in the pnew that a relarelaation informs be intensive research uh today。

now， let's move further。

but still we can england a informers。

wasn't so， michael gaba， a mia r linforicity informs。

a blast mesitically informs嗯。

are you know in the past the a standard treatment once we do him up？。

then let on uh， boto lip， the be tik。

uh indibeitals came along and um it has been shown recently the under my style that the combination of redocuma plus i boto need p superior to redocuma alone。

but now， as you know， there is a new beautiicate， a inebital of chinese origin than a voking it。

and嗯there has been a unddemize a trial comparing is to treatment in business relarelaing or resistant。

general boooennip are shown and higher responsible to do not significant。

but what is important is that for sure， general botennip is less toxic， many less carditotoxic than botting it。

so i guess， the generbootenep is going to become the new standard treatment in a warden of microglobyymia。

mine can selling for mer。

a suoning former a is still not really， really cuable in the majority of the cases， a sureo in ppast， the standard treatment once represented。

yeah， at least in patients were not too old by idoles can mohave AP and a autologgtrtrsplantation in second line。

i don't dn't eus as shown to be the best danketed treatment for uh relaxing patients。

but now probably， we are witnessing a change in our standard approach to the disease。

and this is based on the results of the so cod diangle h。

uh undto my style， in which。

the classical induction keam of plus or dollar with mareldown soundation was compare to the same pregnant plus mamaintenance with。

i boto you during two years or in the curter time。

maintenance sweet， i put to it without。

i old dollar with born elelwas sundundday and based on a。

reviews uh is caninefic study all patient received also。

uh we took him up maintenance。

as you see， this is a you trial with。

more than the hundred patients was enter is a tiet is of been lantommized among the three arms。

the conclusion for the timeing， as say， represented as your last AH meeting is that an ogloabous plus important ity is superial to odoloa 's alone。

our dolabous。

alone eh， it's not to be able to evting it alone without。

um our talllar with动bomarrow trstantation for the time being is sticuearly make make final a decision um。

whether a dollar故事。

approach auorilomomodeconantation still still ask something to ebotit。

what we know is that i bootinep alone is less toxic， and most probably the addition to mauglogial momol concertation ation after standard temodea p and a not detity forma。

we not be superior to aboony alone， which would completely change our approach to monitor selling forma， make make auggsbal marathconcertatation no longer necessary。

let's come to difuse se life， cc uh informal， which is the common st type of noral informms。

we have a note and next， a nonoal viarian is an aggressive disease patients die rapidly if they are not utreated。

and currently securate since many years uh created at currenty to sixty five percent。

so ueveryeverybody is looking for involving that， which has not been the case for the last twenty years。

at the beginning， as you low， we are two um genetic septypes as the activated one in the gminal centre one。

but all the studies trying to creet these spactiof， these two septypes differently。

failed to show show AAA progress。

probably because this is a much too symliicic approach currently。

we have a new molecular classification， which unkon passes at least six servertimes， as you can see and here um。

they are associated to different um modified uh genans， some of a good pochnology sum of an intermedia pop noses， some of a poor pochnoloses。

and。

they are somehow related also to order not not a sufetipe where we are are。

we are is the h to gene is linked to seventy and a mubtidiwhere。

we we MADATA and CD is somehow related to um。

excelaute a informers。

it is important普利，ar ze， which is summarizing dislight that even these sticks， some groups are not origenious。

呃，as you can see here looking at four of them， they still a comcompass a valariable proportion of activated sales of germincenter me sel of unclassifiable， and also looking at um。

is if we look at the activated and the gerine center with you see see that they i comppass a variable proproposal of the six sub groups。

so six sub groups is already better for understanding the difference of the。

among a if you like beselforforal vision tion pasass or just a basketball everything， but it's probably not the end of um of the， we will probably have more subgroups。

uh， the h。

next in the of qufying part of the journal。

but and this is important news， people are starting to use this a serp classification。

and the first do does has been the gope in shanghai， which has presented at the a lugano meeting， a very interesting study。

uh in that study， all patients were treated first with one cycle of our chop。

and then when the molecular supertibing was known。

they et。

an addition item of you， i looking it all of let a little mind or and of an um。

epigenetic modifiers or an h dug modifiers。

so the ID should once depending on the。

sub groups and not like in the studies before which failed where everyone was getting the same addition。

so eah they ed to give。

a cvogated addition based on one of the six and surbrues and see there， um although the thirty is for certime being limited， two， one hundred twenty patients， looking at the a responsibor， a complete responsible， but also APFS of a one year。

our shop is clearly and statistically significantly inferior to the ardrop， plus the target develop base on one of the six， a serb groups。

this is a very important thirty， and you know that嗯。

data fururther da a and longer of is is h in and is still supporting the positivity of that study。

so this is the first study to assign develoapine first line basase on morlesubtime time study is positive shoshowand activvity sube ere do the classiical have job the first study to do so workwide。

so this supports new designs in that uh thanks。

but of course， it will require confirmation in older studies ending bigous study。

since this is a somewhat limited study asaga they are called。

the order aporach es， this study was also presented at logan methis。

this is a another study when they tried to individuze the treatment base on biological race factor。

so in the mk， so the ddble with a inform the be fifty rereforthe rological two mutation， the city， five， the the in factor， just we know negative race factor。

so they um arted with a stop。

so then added。

when the biologiceach factors were uh no either。

嗯，应多数我也。

bad with factor positive a。

i took you those adapted a book intensively。

all they continue in。

those were not be bad。

efactors positive simply with AAR chop or r chop and。

again， the results were positive in the same step in the vast majority of the cases， intensifying the treatment， according to the bad biological risk factors， um was able to improve the results and make the results the same as in patients without bad biological risk factors。

but this was not the case seventeen teen ill ill AA modification city tifice pothe order。

yes。

what about now um cacky ells？um you know that呃，there have been a lot of studies uh trying to position。

a the all of guar descent， of course。

they started in sedary laft。

as i goduyou six percent will be culed with first line treatment， then develops five to ten percent with a second line kem o， plus a dollar born mardel about thirty thirty justify for the peration will have a separary relapps and generally die eithere soon。

it has been shown that counaccells。

and this was the first time that， that happened was able to pure some of these patients。

and therefore， they were then move to second line treatment。

uh， in some undermize drive compcompment as second lotratanty cells in tallogable transplance。

as i ensure you in the moment， and some people are already momove now parity cells to highest patients in first line。

what about the one of my shojup three men an one to my eh trial a comparing um characty cell inversy laps to the standard treatment before， which is i losee more plus autolophs。

rule of game。

哎。

a positive at least based on the publications one is negative。

and i can already tell you that next， we will last the long， a longer fulow up of all the three surggetion that my chamber was the time being two positive， one negative。

嗯，so呃results are somewhat uh contrographh hoably。

we are still to understand。

which are the patients who can really profit more from the use of capticiells and probwer， which are the patients who are primarily assistant to cafeticells or become resistant very soon。

now um as you know， on enjoy the side java。

now uh a lot of new。

嗯。

be specific antibody dies a body， just just one of the issues es of blood。

very good review， present ted， the um so the pthe first first for toxic for a sic， a very good， a xic for paxic s specific。

very forremost。

the new one， they one， a five for six。

i don't don't tell the time to discuss was very last high， the first one。

a long didition of response， and they are much less toxic than uwe。

we know to moup up and also less toxic， many related to CNS than a coffety cell。

so。

the big question today is。

which is better counacty cells or be specific monoconal antibodies。

um if if you just to bet i you like a beg for the specific monoon on ani bodies。

but i guess that for the future， the way to go will be to integrate all the treatments， the standard， chemo， l， the artty cell， the be specific。

in order to be able to diommatically improve are blast。

a also the outcome in a defuse be selling only dedepks of the same reserves as those that we have currentee in aukilinform。

so concluding for a not informers。

if you like selling former is not just one disease， we have the first positive results from study considering genetic capitmalities in biommarket。

this is a big noberty ties among the new drugs and did have time to discuss that are the most promising ones。

guasy cells and specispecificant body body。

they will be practice changing。

although the preliminary results in facstory diagarcises are still so much control version， but we are looking forward to us and you and data longer for the up and on the otter side。

the results of improved thanks to the better biological understanding that we have。

but there is a lot。

of a new research going on。

and we。

i'm getting raradly more uh biological understanding， so that i am sure that very soon。

we will laugh still you get have a beauty possibilities， and i don't doubt that very soon。

we will achieve。

older important back tools in the treatment of laveout， if feels like be selling for me。

这个工作二维码病例。

exa a inform。

i don't just have to consider all of them just two。

allocations by mcy informer switch， where to what's one in the past。

we demonstrated a few years ago that呃。

i those are see AB less。

i those metro tracks。

that is superior。

you two。

i those metro tracks that alone this one stands pivate of study comparing。

just stand up with additional al。

we took him up and difital mamaics and and progbetween eh。

may you get a be on the CNS and because our in since today in qantas。

we do pass when almost all of them were die today。

a lot of them as you can see。

are living long， and some many of them are cured。

we have to take note and try to avoid the CNSTX situation in the past。

a didn't didn't matter。

so the results here asked umost ATS， as you can see in with the mameicc aggement， which is absolutely superior to the two orders。

uh。

the majority of patience are still surviving and being uh in a response。

and the other an important uh result is that。

um the addition of rea make difference。

so we might avovoid and the at the next meeting to avoid in the same time。

in the maintenance phase， i doles chemo to uh unknown cost resistem and non high those se chemo caerapy。

by mary magiciine have be selling forms， which is not too common， but very important because opperation are very young。

here， the controversies should we still add vigio canava b to the呃，initial induption？。

MR kimo give AB， as it has been the standards to por is is the r mmo enough us。

the NCI group。

uh was proposing， but based only on a limited face to trial。

so we decided in order to answer ve this important question because we would all very much like to avoid traventia p to mesroom in this very young patients。

we have come it out undermimy uh trial where。

patients in metabolic complete response uh uh wandomze um to a little give AB or two observation only。

we included five hundred five patients， as you can see some of china china started very late， but um included in some of as a patients。

and as we have already shown， but we know is that um as we p twenty one should no longer be used because it is infior to order are。

一模样ava鼻ast。

are a dozis aapted a book or after shop fourteen， but not after shop a twenty one。

as regards， whether they you ever be is necessary or not。

i cannot use the answer， although i have the answer， but the answer will be presented at the next ICMM mic in rogano。

and so i hope that you will be able to uh see this uh important information。

conclusion for exand other informers， i didn't have time to show you or the stisticular lar dolgha location。

but in general， there has been a huge improvement in the last years， in most location， since we have learned graph。

a different shaated and a ducted treatment to different allocation。

and in the primary majestina informer， and we know that imppatients were relaps。

and those are very few very， very few check point。

indivitals are very active since by my majestina disinformer is very similar to auchking informers。

and we are trying now which not perperent cure by not ding， check point indivitals to the treatment at the beginning are in the first line treatment。

just conclude， since i am looking to the usually um members um our group， the international lift informer study group h is conducting as the sponsor AH trial in shanghai， a in ducas a jtap p plus jckp HSKELA informal uh in first line。

um we do not affort yet the end results。

but this is just to show you that。

we are very much interested in collabating ating intensivevely h。

we do the swiss government also also given us some support ort we opp in the next year to be able to expand collaboration in many utrials with order members of uureally。

to conclude after thanking you for the attention。

um i hope the menu few will be able to come to organo HI can already get ate you now that the we are receiving， as you know。

the deadline is much fifteen， but we are receiving a lot of very， very interesting， uh abstract。

most of them will not be present the dask for or at yeah。

so i hope that you will come to ube with us as this uh conference， which呃。

as we congest now look as one of the best ones， which we we are in the bus。

thank you very much and see you in organo and deep， not in organa inciamman。

thank you。